Tumor Lysis Syndrome Management in Venetoclax Patients

Introduction to TLS Management

The American Society of Hematology recommends loop diuretics like furosemide (Lasix) may be required to maintain adequate urine output (≥100 mL/hour in adults) during hydration for tumor lysis syndrome prevention, but only after confirming adequate hydration status and ruling out obstructive uropathy or hypovolemia 1, 2

Before administering furosemide, it is crucial to verify hydration status is adequate by checking urine osmolality and fractional excretion of sodium to confirm the patient is truly volume-replete, not hypovolemic 1, 2
The European Society for Medical Oncology suggests that loop diuretics are contraindicated in patients with urinary obstruction 1, 2
Hemodynamic stability should be assessed by evaluating blood pressure and perfusion before initiating diuretics, as recommended by the American College of Cardiology 1

The National Comprehensive Cancer Network recommends targeting a urine output of ≥100 mL/hour in adults (3 mL/kg/hour in children <10 kg) through aggressive intravenous hydration 1, 2
Hydration should ideally start 48 hours before venetoclax initiation when possible, according to the American Society of Clinical Oncology 1, 2
The administration of 3L/m² of IV fluids is recommended to achieve and maintain target urine output, as suggested by the European Society for Medical Oncology 2

The American Society of Hematology recommends allopurinol 100 mg/m² three times daily (max 800 mg/day) for intermediate-risk patients 1, 4
Rasburicase 0.20 mg/kg/day IV over 30 minutes is recommended for high-risk patients (those with high tumor burden, elevated baseline LDH, or renal impairment) by the National Comprehensive Cancer Network 1, 2, 4
The concurrent administration of allopurinol and rasburicase is not recommended, as it causes xanthine accumulation, according to the European Society for Medical Oncology 1, 4

The American College of Cardiology recommends monitoring LDH, uric acid, sodium, potassium, creatinine, BUN, phosphorus, and calcium every 12 hours for the first 3 days 1, 2
Vital signs, urine output, electrolytes, and renal function should be monitored every 6 hours for the first 24 hours, as suggested by the American Society of Clinical Oncology 1, 2

The European Society for Medical Oncology advises against alkalinizing urine, as it increases calcium phosphate precipitation risk and doesn't improve outcomes 3, 5, 6
The American Society of Hematology recommends not giving diuretics to hypovolemic patients, as it worsens renal perfusion and increases TLS complications 1